Docket Number:13A-1030918
Inventor:Yi-Ping Hsueh, Yu-Tzu Shih
IP Status:TW patent, US patent pending
Abstract:
Neurofibromatosis type I (NF1) is a common autosomal dominant disorder with a prevalence of 1:3500. It is characterized by a wide variety of clinical manifestations including learning disabilities, attention deficit and impairments in social interaction. NF1 proteins interact with valosin-containing protein (VCP), a causative gene for inclusion body myopathy associated with Paget’s disease of bone and frontotemporal dementia, amyotrophic lateral sclerosis and autism spectrum disorders, to regulate dendritic spine formation that is associated with learning difficulties and memory deficits in patients. Here, we suggest an easier way to ameliorate the neurological symptoms of these two diseases in rodent models.
Fields of Application:
Neurological symptoms of NF1 and VCP-related diseases.
Advantages when compared to the existing technologies:
There is no existing medicine for neurological symptoms of NF1 and VCP-related diseases.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
